AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
VIENNA -- The use of magnesium sulfate for the treatment of preeclampsia does not appear to increase the long-term risk of death or neurosensory disability in children. Lelia Duley, M.D., reported at the 14th World Congress of the International Society for the Study of Hypertension in Pregnancy.
The findings come from a follow-up study of subjects who participated in the landmark multinational Magpie (Magnesium Sulfate for Prevention of Eclampsia) Trial, in which 10,141 pregnant women with preeclampsia--from the developed and the developing world--were randomized to receive magnesium sulfate (MgS[O.sub.4]) or placebo. Women who received MgS[O.sub.4] had a 58% lower risk of eclampsia and a 45% lower risk of death, with no clear difference in the risk of death among the newborns up until the time of hospital discharge (Lancet 2002;359:1877-90).
Now, an 18-month follow-up among 4,782 women and 4,483 children from the original trial suggests that in utero exposure to the drug is not associated with long-lasting damage. "It's very reassuring," said Dr. Duley an obstetric epidemiologist at the Resource Center for Randomized Trials, Institute of Health Sciences, Oxford, England.
A total of 13.9% of the children of the mothers who received MgS[O.sub.4] before delivery had died by the time of follow-up, not ...
Source: HighBeam Research, MgS[O.sub.4] does not raise disability risk in children: follow-up...